Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy

Next Previous
Trial Profile

An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access
  • Acronyms PANEX
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 28 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
  • 04 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top